INT-767

• Description :

  INT-767 is a dual farnesoid X receptor (FXR) /TGR5 agonist with mean EC50s of 30 and 630 nM, respectively[1][2].

• UNSPSC :

  12352100

• Target :

  Autophagy; FXR; G protein-coupled Bile Acid Receptor 1

• Type :

  Reference compound

• Related Pathways :

  Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/INT-767.html

• Purity :

  99.81

• Solubility :

  DMSO : ≥ 100 mg/mL|H2O : 100 mg/mL (ultrasonic)

• Smiles :

  C[C@H](CCOS(=O)(O[Na])=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@@]21C

• Molecular Formula :

  C25H43NaO6S

• Molecular Weight :

  494.66

• References & Citations :

  [1]Baghdasaryan A, et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mousecholangiopathy model by promoting biliary HCO3- output. Hepatology. 2011 Oct;54 (4) :1303-1312.|[2]Rizzo G, et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor andTGR5 agonist. Mol Pharmacol. 2010 Oct;78 (4) :617-630.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1000403-03-1]